{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:47:07Z","timestamp":1762174027649,"version":"build-2065373602"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["P30EY025585(BA-A)","P30EY025585(BA-A)"],"award-info":[{"award-number":["P30EY025585(BA-A)","P30EY025585(BA-A)"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study assesses the predictiveness of retinal thickness variability on long-term visual acuity (VA) outcomes in patients with diabetic macular oedema (DMO) undergoing anti-VEGF therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Retrospective chart review at a single institution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants:<\/jats:title>\n                    <jats:p>184 and 138 patients underwent initial treatment for DMO and continued to follow-up at 3 and 5 years, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Baseline demographics, past medical, and clinical data were collected through electronic medical record query. Central subfield thickness (CST), choroidal volume (CV), and cube average thickness (CAT) variability over the first year of treatment were calculated using standard deviation, amplitude, and area under the curve. CST, CV, CAT, and best corrected visual acuity (BCVA) were noted at the initial treatment date and 3 and 5 years. CST variability quartiles were compared on baseline, final, and change in BCVA alongside final and change in CST. Multiple linear regression was used to evaluate factors associated with final BCVA at 3 and 5 years while adjusting for confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>There is no significant association between larger fluctuations in macular thickness and change in BCVA at 3 and 5 years. Individuals in the highest CST variability quartile had the lowest final BCVA but also the lowest baseline BCVA and no difference in BCVA change. Linear regression revealed that CST variability was not predictive of final BCVA. Baseline BCVA and total number of anti-VEGF injections were predictive of BCVA at 3 years and 5 years respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Macular thickness variability did not predict long-term visual outcomes at 3 and 5 years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-025-03968-y","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T17:18:35Z","timestamp":1757697515000},"page":"2933-2939","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the long-term predictive value of macular thickness fluctuations on diabetic macular oedema response to anti-VEGF treatment"],"prefix":"10.1038","volume":"39","author":[{"given":"Taseen","family":"Alam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Maatouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0458-4181","authenticated-orcid":false,"given":"Katherine E.","family":"Talcott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"3968_CR1","first-page":"0","volume":"2018","author":"G Virgili","year":"2018","unstructured":"Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2018;2018:0\u20130 .","journal-title":"Cochrane Database Syst Rev"},{"key":"3968_CR2","doi-asserted-by":"publisher","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","volume":"127","author":"CJ Flaxel","year":"2020","unstructured":"Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Diabetic retinopathy preferred practice pattern. Ophthalmology. 2020;127:P66\u2013P145.","journal-title":"Ophthalmology"},{"key":"3968_CR3","first-page":"1","volume":"2016","author":"P Romero-Aroca","year":"2016","unstructured":"Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R, et al. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. Exp Diab Res. 2016;2016:1\u201317.","journal-title":"Exp Diab Res"},{"key":"3968_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"QD Nguyen","year":"2012","unstructured":"Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789\u2013801.","journal-title":"Ophthalmology"},{"key":"3968_CR5","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","volume":"121","author":"J-F Korobelnik","year":"2014","unstructured":"Korobelnik J-F, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247\u201354.","journal-title":"Ophthalmology"},{"key":"3968_CR6","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.oret.2020.05.018","volume":"4","author":"AX Chen","year":"2020","unstructured":"Chen AX, Greenlee TE, Conti TF, Briskin IN, Singh RP. Fluctuations in macular thickness in patients with retinal vein occlusion treated with anti-vascular endothelial growth factor agents. Ophthalmol Retin. 2020;4:1158\u201369.","journal-title":"Ophthalmol Retin"},{"key":"3968_CR7","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.2147\/OPTH.S173956","volume":"ume 12","author":"S-J Sheu","year":"2018","unstructured":"Sheu S-J, Lee Y-Y, Horng Y-H, Lin H-S, Lai W-Y, Tsen C-L. Characteristics of diabetic macular edema on optical coherence tomography may change over time or after treatment. Clin Ophthalmol. 2018;ume 12:1887\u201393.","journal-title":"Clin Ophthalmol"},{"key":"3968_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2017.05.014","volume":"180","author":"WC Ou","year":"2017","unstructured":"Ou WC, Brown DM, Payne JF, Wykoff CC. Relationship between visual acuity and retinal thickness during anti-vascular endothelial growth factor therapy for retinal diseases. Am J Ophthalmol. 2017;180:8\u201317.","journal-title":"Am J Ophthalmol"},{"key":"3968_CR9","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/archophthalmol.2012.1107","volume":"130","author":"SB Bressler","year":"2012","unstructured":"Bressler SB. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol. 2012;130:1153.","journal-title":"Arch Ophthalmol"},{"key":"3968_CR10","doi-asserted-by":"crossref","unstructured":"Browning DJ, Glassman AR, Aiello LP, Beck RW, Brown DM, Brown DM, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology. 2007;114:525\u201336.","DOI":"10.1016\/j.ophtha.2006.06.052"},{"key":"3968_CR11","unstructured":"Islam F, Islam F. Retinal thickness and visual acuity in diabetic macular edema: an optical coherence tomography-based study. J College Phys Surg Pak. 2016;26:598\u2013601."},{"key":"3968_CR12","doi-asserted-by":"crossref","unstructured":"Bressler NM, Odia I, Maguire MG, Glassman AR, Jampol LM, MacCumber MW, et al. Association between change in visual acuity and change in central subfield thickness during treatment of diabetic macular edema in participants randomized to aflibercept, bevacizumab, or ranibizumab: a post hoc analysis of the protocol t randomized clinical trial. JAMA Ophthalmol. 2019;137:977\u2013985.","DOI":"10.1001\/jamaophthalmol.2019.1963"},{"key":"3968_CR13","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1039\/C8LC00659H","volume":"18","author":"F Farjood","year":"2018","unstructured":"Farjood F, Vargis E. Novel devices for studying acute and chronic mechanical stress in retinal pigment epithelial cells. Lab a Chip. 2018;18:3413\u201324.","journal-title":"Lab a Chip"},{"key":"3968_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1167\/iovs.61.12.7","volume":"61","author":"LP Evans","year":"2020","unstructured":"Evans LP, Boehme N, Wu S, Burghardt EL. Associations between variation in retinal thickness and visual function. Investigative Ophthalmol Vis Sci. 2020;61:7.","journal-title":"Investigative Ophthalmol Vis Sci"},{"key":"3968_CR15","doi-asserted-by":"crossref","unstructured":"Wang VY, Kuo BL, Chen AW, Chen AX, Chen AX, Chen AX, et al. Fluctuations in macular thickness in patients with diabetic macular oedema treated with anti-vascular endothelial growth factor agents. Eye. 2021;36:1461\u20131467.","DOI":"10.1038\/s41433-021-01672-1"},{"key":"3968_CR16","first-page":"1046","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing Snellen visual acuity measurements. Retin- J Retinal Vitreous Dis. 2010;30:1046\u201350.","journal-title":"Retin- J Retinal Vitreous Dis"},{"key":"3968_CR17","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/jamaophthalmol.2018.3848","volume":"136","author":"GG De\u00e1k","year":"2018","unstructured":"De\u00e1k GG, Schmidt-Erfurth UM, Jampol LM. Correlation of central retinal thickness and visual acuity in diabetic macular edema. JAMA Ophthalmol. 2018;136:1215.","journal-title":"JAMA Ophthalmol"},{"key":"3968_CR18","doi-asserted-by":"crossref","unstructured":"Campos A, Campos EJ, Carmo A do Caramelo F, Martins J, Martins J, et al. Evaluation of markers of outcome in real-world treatment of diabetic macular edema. Eye Vis (Lond). 2018;5:27.","DOI":"10.1186\/s40662-018-0119-9"},{"key":"3968_CR19","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","volume":"132","author":"JK Sun","year":"2014","unstructured":"Sun JK, Lin MM, Lammer J, Prager S, Sarangi R, Silva PS, et al. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with center-involved diabetic macular edema. JAMA Ophthalmol. 2014;132:1309.","journal-title":"JAMA Ophthalmol"},{"key":"3968_CR20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.visres.2017.03.008","volume":"139","author":"BS Gerendas","year":"2017","unstructured":"Gerendas BS, Bogunovic H, Sadeghipour A, Schlegl T, Langs G, Waldstein SM, et al. Computational image analysis for prognosis determination in DMO. Vis Res. 2017;139:204\u201310.","journal-title":"Vis Res"},{"key":"3968_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ajo.2021.06.030","volume":"232","author":"MR Starr","year":"2021","unstructured":"Starr MR, Salabati M, Mahmoudzadeh R, Patel LG, Ammar MJ, Hsu J, et al. Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting. Am J Ophthalmol. 2021;232:90\u20137.","journal-title":"Am J Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03968-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03968-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03968-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:06:15Z","timestamp":1762171575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03968-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":21,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3968"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03968-y","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"type":"print","value":"0950-222X"},{"type":"electronic","value":"1476-5454"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KET reports personal fees from Alimera, Abbvie, Apellis, Astellas, Eyepoint, Genentech, Outlook, Regeneron, and Zeiss, and research fees from Regeneron and Zeiss.RPS reports personal fees from Apellis, Iveric, Eyepoint, Regnenxbio, Genentech, Bausch and Lomb, Zeiss, and sponsored research from Janssen. All other authors report no disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}